ZURICH Oct 4 Roche said on Tuesday its
lung cancer drug Alecensa (alectinib), developed by its
Genentech unit, received a second breakthrough therapy
designation (BTD) from the U.S. Food and Drug Administration
(FDA) for its anaplastic lymphoma kinase (ALK) inhibitor.
The latest BTD was granted for the treatment of adult
patients with advanced ALK-positive non-small cell lung
cancer (NSCLC) who have not received prior treatment with an ALK
inhibitor, the Swiss drugmaker said in a statement.
Alecensa received its first FDA BTD in June 2013 for people
with ALK-positive NSCLC whose disease progressed on treatment
with crizotinib, Basel-based Roche said.
(Reporting by Silke Koltrowitz)